venous thromboembolism
Cardiovascular · 2012–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| enoxaparin Treatment and prophylaxis of venous thromboembolism, including deep vein thrombosis, in patients requiring higher doses (>100 mg) who would otherwise require… | Jul 2019 | Recommended | unclear |
| enoxaparin Prophylaxis or treatment of deep vein thrombosis (DVT) and venous thromboembolism (VTE) prophylaxis, with particular focus on extended VTE prophylaxis in… | Mar 2019 | Recommended with restriction | input received |
| warfarin Prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism; prophylaxis and/or treatment of thromboembolic complications… | Nov 2016 | Not recommended | none received |
| apixaban Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent venous thromboembolism following initial treatment. | Mar 2015 | Recommended with restriction | none received |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation at risk of stroke (prior stroke/TIA/non-CNS systemic embolism or… | Mar 2012 | Recommended with restriction | unclear |
What the PBS pays
$478M in government benefit over 2024–25, across 8,313,444 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| apixaban | $308.7M |
| rivaroxaban | $128M |
| enoxaparin | $32.5M |
| warfarin | $8.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| rivaroxabanRivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | recommended | 2013-06 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| phenindioneDINDEVAN 10mg tablet | 1991 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.